The relationship between anemia and Kt/V index in patients undergoing continuous ambulatory peritoneal dialysis and hemodialysis

Boshra Hasanzamani, Mahin Ghorban Sabbagh

Kidney Transplantation Complications Research Center, Department of Internal Medicine, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

**Implication for health policy/practice/research/medical education:**
In a study on 57 patients with ESRD on continuous ambulatory peritoneal dialysis and hemodialysis, we found anemia was mostly observed in patients receiving hemodialysis as compared to continuous ambulatory peritoneal dialysis. Regardless of the type of dialysis, adequacy of dialysis did not affect incidence of anemia in any of the groups.

Please cite this paper as: Hasanzamani B, Ghorban Sabbagh M. The relationship between anemia and Kt/V index in patients undergoing continuous ambulatory peritoneal dialysis and hemodialysis. J Renal Inj Prev. 2020; 9(1): e06. DOI: 10.15171/jrip.2020.06.

**Introduction:** Anemia in end-stage renal disease (ESRD) can cause serious problems for patients.

**Objectives:** The present study was conducted to investigate whether the type or adequacy of dialysis can affect the incidence of anemia in these patients.

**Patients and Methods:** This cross-sectional study was conducted on 57 patients with ESRD, who were referred to Qaem and Imam Reza hospitals, Mashhad, Iran. The patients were divided into two groups of continuous ambulatory peritoneal dialysis (CAPD) (n=37 patients) and hemodialysis (n=20 patients). Patients had no laboratory evidence of iron deficiency or hyperparathyroidism. Enrolled patients were received vitamin B12 and folic acid too. Hemoglobin concentration of under 11 mg/dL was considered as anemia. Adequacy of dialysis was evaluated by Kt/V index (>1.2 for hemodialysis and >1.7 per week for peritoneal dialysis). We compared different factors in these two groups, including anemia and Kt/V, and evaluated their relationship.

**Results:** Around 27% and 65% of the patients on CAPD and hemodialysis were anemic respectively ($P=0.005$). Adequacy of dialysis in CAPD was acceptable in 81.1% of the cases, while target Kt/V was achieved in 50% of the patients on hemodialysis. Dialysis adequacy was significantly higher in patients receiving CAPD ($P=0.014$). No significant correlation between the incidence of anemia and Kt/V in both types of dialysis was found ($P>0.05$).

**Conclusion:** Anemia was mostly observed in patients receiving hemodialysis as compared to CAPD. Regardless of the type of dialysis, adequacy of dialysis did not affect the incidence of anemia in any of the groups.
advantages and disadvantages (9).

Erythropoietin (EPO) is a hormone produced by the kidneys, which helps with management of anemia and is known as the main global treatment during dialysis process. Commonly, before using EPO, the rate of blood transfusion is lower in patients undergoing PD as compared to those receiving HD (10). This leads to lower percentage of anemia in patients on PD in comparison with HD (11). In addition, treatment response to anemia is better in patients treated with PD compared to patients with HD (12). The production of EPO by peritoneal macrophages (6) and losing a little blood during dialysis procedure then in HD are some interacted factors. Additionally, continuous fluid replacement leading to hemoconcentration, and exodus of uremic inhibitors of EPO synthesis lead to better treatment of anemia in patients undergoing PD (10).

Anemia is usually associated with reduced exercise capacity, fatigue, generalized coldness, anorexia, insomnia, depression, cognitive dysfunction, decreased libido, development of left ventricular hypertrophy, and related problems in affected individuals (4). Kt/V index is a criterion applied to measure the quality of HD and PD adequacy, which is dependent on the pre- and post-dialysis urea concentration. There are few studies comparing the severity of anemia in patients on PD and HD by using Kt/v index.

Objectives
The present study was designed to investigate the effect of dialysis adequacy on the incidence of anemia.

Patients and Methods
Study patient
This cross-sectional study was performed on 57 ESRD patients, who were referred to Qaem and Imama-Reza hospitals, Mashhad, Iran. The participants were divided into two groups of CAPD (n=37) and HD (n=20). In the patients on CAPD (using the Twinbag system [Samen, Iran]), the mean duration of treatment was 25 months (range; 6-65 months) and those in the HD group were treated for at least six months three times a week, each time for 4 hours.

There was no evidence of iron deficiency (ferritin >100 ng/mL and transferrin saturation >20%) or hyperparathyroidism (parathyroid hormone <300 pg/mL) in our patients. There was no history of a significant infectious disease (including peritonitis) among the patients. Patients had anemia (hemoglobin <11 g/dL) and were treated with recombinant human erythropoietin (rh-Epo) before entering the study. All the patients were receiving supplemental folic acid and vitamin B12. All the patients had acceptable nutritional condition, which was assessed by measuring serum albumin with a mean of 3.9 g/dL (range; 3.5-4.9 g/dL) in the CAPD group and 4.1 g/dL (3.6-4.6 g/dL) in the HD group.

The efficacy of blood purification was assessed based on the Kt/V index. Kt/V>1.2 for HD patients and Kt/V>1.7 per week for CAPD patients were considered adequate. Similar laboratory and commercial kits were used to examine the patients.

Ethical issues
The research followed the tenets of the Declaration of Helsinki. Informed consent was obtained. The ethical committee of Mashhad University of Medical Sciences approved the research (Ref # 98/1167/04). All patients’ information remained confidential.

Statistical analysis
Data were imported into SPSS version 16 and analyzed using Pearson’s correlation coefficient. Additionally, P value of less than 0.05 was considered statistically significant.

Results
The data showed that 54.1% of the patients undergoing CAPD were male and the mean age of this group of patients was 54.4 years (age range 20-85 years). In addition, 70% of patients in the HD group were male and their mean age was 42.8 years (age range; 18-75 years). In the CAPD group, ESRD was due to chronic glomerulonephritis, diabetic nephropathy, hypertensive nephropathy, adult polycystic kidney disease (ADPKD), and unknown etiologies in 10%, 30%, 22%, 14%, and 24% of the cases, respectively. In the HD group, it was due to chronic glomerulonephritis, diabetic nephropathy, hypertensive nephropathy, ADPKD, and unknown etiologies in 5%, 25%, 35%, 10%, and 25% of the cases, respectively. Descriptive statistics of the para-clinical data are shown in Table 1.

A statistically significant correlation between type and adequacy of dialysis in this study was found. Thirty (81%) patients on CAPD had Kt/V>1.7 per week, but only 10 (50%) of those on HD had Kt/V>1.2. There was a significant difference between two groups regarding of Kt/V index (P=0.014). About 27% of the patients in the...
CAPD group were anemic, while 65% of the patients in the HD group had anemia. There was a statistically significant relationship between type of dialysis and incidence of anemia \((P=0.005)\). The severity of anemia was evaluated based on Kt/V index in all the patients and separately in each group, but the difference was not statistically significant \((P=0.934)\), as demonstrated in Table 2.

**Discussion**

This study was the first attempt to evaluate the relationship between anemia and Kt/V index in ESRD patients undergoing CAPD and HD. According to our study, a statistically significant relationship was found between type and adequacy of dialysis. In other words, patients undergoing CAPD had higher Kt/V index compared to the patients on HD. In addition, a statistically significant association between type of dialysis and incidence of anemia was detected.

Our findings were in line with those of other studies. It is believed that anemia management is easier in patients receiving PD than in those on HD. Some studies revealed that anemia is controlled by lower EPO doses in patients receiving PD as compared to HD \((10,13)\).

The reasons for blood loss are different in patients on PD as compared to HD. In PD, the extracorporeal circuit is used for carrying the blood outside the body. In addition, repeated venous puncture and entrapment of RBCs in the dialyzer are the other reasons behind lower blood loss in PD patients. Higher anemia severity in patients undergoing HD compared to those on PD is due to the maximal plasma volume expansion during blood sampling for hemoglobin \((14)\).

Since anemia can be affected by dialysis quality \((15)\), one of the issues of concern in this study was dialysis adequacy. In accordance with our study, the obtained results of Coronel et al. \((16)\), showed that the required EPO doses for correction of anemia were lower in patients on PD than in patients receiving HD. According to that study, to obtain the same hemoglobin level with the same administration dose, lower EPO doses were required in patients undergoing PD than in those on HD. As we know, EPO is a hormone produced by the kidneys that enhances RBC formation \((10)\). Our study showed a statistically significant association between type of dialysis and incidence of anemia.

Some studies did not find any relationship between dialysis adequacy and EPO resistance \((17)\). However, this is not an adequate reason to reject our findings, as this discrepancy may be as a result of unknown confounding variables. The role of Kt/V index in the occurrence of anemia and its relative importance is not clear yet. Several studies showed that a low Kt/V index indicates anemia, which necessitates higher EPO dose to maintain target plasma hemoglobin levels \((18,19)\). However, some studies found no association between them \((12)\). Our data showed no significant relationship between these variables, as well.

Anemia and a secondary need for recombinant human erythropoietin (rhEPO) increases during peritonitis in CAPD patients \((20)\). Patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may show higher rate of anemia due to rh-EPO hypo-responsiveness \((21)\). Some studies proposed a correlation between anemia (rh-EPO hypo-responsiveness) and hypoalbuminemia \((18)\). According to the above-mentioned data, we designed the exclusion criteria so that these factors would not affect our results. Iron deficiency, blood loss, infection, and inflammation are considered as factors contributing to anemia \((10, 22)\). The effect of albumin per se on hematocrit or erythropoiesis has not been proven yet. In accordance with other similar studies \((13)\), serum albumin level was lower in the CAPD group when compared to the HD group in our study, however, it was normal in both groups. Additionally, ferritin level was higher in patients on HD in comparison with CAPD, which may be due to higher risk of developing iron deficiency in HD patients \((10)\).

Coronel et al \((16)\) investigated the parathyroid hormone level, which was higher in patients receiving HD than those undergoing PD. Although patients with more severe hyperparathyroidism were not significantly different in the two groups. In our study, none of the patients had hyperparathyroidism or evidence of iron deficiency. Therefore, the obtained results of this study can be used with more certainty to assess the relationship between anemia and type of dialysis.

We investigated the frequency of comorbidities in ESRD patients. Severe hyperparathyroidism is one of the leading causes of anemia. Nevertheless, some authors found no relationship between these variables \((17)\).

**Conclusion**

As demonstrated in our study and several other clinical trials, anemia is observed in patients undergoing HD more commonly than those on CAPD, which can be deemed as a drawback for HD. However, we did not find...
any significant relationship between anemia and dialysis adequacy.

Limitations of the study
This investigation was conducted on a limited proportion of dialysis patients and we suggest larger investigation on this aspect of HD patients. In our study, the patients in the two groups were different regarding age and dialysis duration. Therefore, our findings might be affected by differences between the groups.

Acknowledgments
We would like to thank all staff of hemodialysis and peritoneal dialysis centers of Ghaem and Eman-Reza hospital-Mashhad University of Medical Sciences, and all those who have helped us in this study.

Authors’ contribution
BHZ and MGS both conducted the research, searched the literature and analyzed the data and prepared the draft. All authors read, revised and approved the final manuscript.

Conflicts of interest
There were no points of conflict to declare.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support
None.

References
1. White P. Stedman’s Medical Dictionary for the Health Professions and Nursing. Reference Reviews. 2013;19:45-6. doi: 10.1108/09504120510632804
2. Kaiafa G, Kanellos I, Savopoulos C, Kakateis N, Giannakoulas G, Hatzitolios A. Is anemia a new cardiovascular risk factor? Int J Cardiol. 2015;186:117-24. doi: 10.1016/j.ijcard.2015.03.159.
3. Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8:56–61. doi: 10.1136/heartasia-2016-010809.
4. Shahbazian H, Ghobani A, Zafar-Mohtashami A, Balali A, Al-Ali A, Lashkarla GR. Administration of pentoxifylline to improve anemia of hemodialysis patients. J Renal Inj Prev. 2016;6:61-4. doi: 10.15171/jrip.2017.11.
5. Vincent JL, Abraham E, Kochanek P, Moore FA, Fink MP. Textbook of critical care: expert consult premium. Philadelphia: Elsevier Health Sciences; 2011.
6. Uthman E. Understanding Anemia. University Press of Mississippi; 2009.
7. Astor BC, Matsushita K, Ganaevoort RT, Van Der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79:1331–40. doi: 10.1038/ki.2010.550.
8. Brady CA. Dialysis without Fear: A Guide to Living Well on Dialysis for Patients and Their Families. Nephrol Nurs J. 2009;36:73-5.
9. Sinnakrounehan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis. 2011;18:428-32. doi: 10.1053/j.ackd.2011.09.001.
10. Lawler EV, Bradbury BD, Fonda JR, Ganzino JM, Gagnon DR. Transfusion Burden among Patients with Chronic Kidney Disease and Anemia. Clin J Am Soc Nephrol. 2010;5:667-72. doi: 10.2215/CJN.06020809.
11. Wetmore JB, Peng Y, Monda KL, Kats AM, Kim DH, Bradbury BD, et al. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis. Am J Nephrol. 2015;4:354-61. doi: 10.1159/000431335.
12. Frietet J, Tvedegaard E, Bruun K, Steffensen G, Cintin C, Breddam M, et al. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly: Peritoneal dialysis international. Perit Dial Int. 1996;16:594-8.
13. House AA, Pham B, Pagé DE. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. Nephrol Dial Transplant. 1998;13:1763-9. doi: 10.1093/ndt/13.7.1763.
14. Eckardt KU. Anemia correction—does the mode of dialysis matter? Nephrol Dial Transplant. 2000;15:1278-80.
15. Locatelli F, Del Vecchio L, Andrulli S. The modality of dialysis treatment: does it influence the response to erythropoietin treatment? Nephrol Dial Transplant. 2001;16:1971-4. doi: 10.1093/ndt/16.10.1971.
16. Coronel F, Herrero JA, Montenegro J, Fernandes C, Gandara A, Conesa J, et al. Erythropoietin requirements: comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol. 2003;16:697-702.
17. Gunnell J, Yean YJ, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33:63-72. doi: 10.1016/S0272-6386(99)70259-3.
18. Kim JK, Park BS, Park MJ, Choi W, Ma SK, Nah MY, et al. The predictive parameters of erythropoietin hyporesponsiveness in patients on continuous ambulatory peritoneal dialysis. Korean J Intern Med. 2001;16:110-7. doi: 10.3904/kjim.2001.16.2.110.
19. Wei M, Bargman JM, Oreopoulos DG. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol. 2007;39:935–40. doi: 10.1007/s11255-007-9226-6.
20. Amon O, Altrogghe H, Kemper M, Srethuaj J, Mülller-Wiel DE. Increased need of erythropoietin during peritonitis in children on continuous peritoneal dialysis. Adv Perit Dial. 1994;10:318-20.
21. Nakamoto H, Kanno Y, Okada H, Suzuki H. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Advances in peritoneal dialysis Conference on Peritoneal Dialysis. Adv Perit Dial. 2004;20:111-6.
22. Macdougall IC. Right response predicts erythropoietin resistance in hemodialysis patients. Am J Kidney Dis. 1999;33:63-72. doi: 10.1016/S0272-6386(99)70259-3.

Copyright © 2020 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.